Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Neutralizing SARS-CoV-2 via S protein

A new study published on the preprint server bioRxiv* in May 2020 reports on a method to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by destroying its main spike protein, which is responsible for attachment to the host cell membrane.

10 May 2020

Antibodies from llamas may hold cure for novel coronavirus SARS-CoV-2

As scientists across the globe race to find an effective treatment for the novel coronavirus, a team of scientists believe that a four-year-old llama named Winter may hold the key to fight the coronavirus disease (COVID-19).

7 May 2020

Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2

Twist Bioscience Corporation has identified competitive antibodies to SARS-CoV-2, which could potentially be used for diagnostic tests and treatments.

7 May 2020

Israeli scientists discover monoclonal antibody that neutralizes SARS-CoV-2

Now, in a significant medical breakthrough, Israel's Institute for Biological Research Institute (IIBRI) has wrapped up the development of a potential treatment for the coronavirus disease. The scientists say they have identified an antibody that neutralizes SARS-CoV-2.

5 May 2020

New information on viral antigens could improve COVID-19 testing

Researchers in France and China have characterized antibody responses to a wide range of antigens present on severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) among patients with coronavirus disease 2019 (COVID-19).

4 May 2020

Newly identified antibody prevents SARS-CoV-2 virus from infecting cultured cells

Researchers at Utrecht University, Erasmus Medical Center and Harbour BioMed (HBM) today reported that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells.

4 May 2020

Temple University Hospital is offering COVID-19 clinical trials, investigational treatments options

Temple University Hospital is now participating in a variety of clinical trials that are testing investigational treatment options for patients diagnosed with the novel coronavirus, or COVID-19.

30 Apr 2020

Arthritis drug assessed as potential treatment for COVID-19-related pneumonia

UC San Diego Health has launched a Phase III clinical trial, part of a global effort, to assess whether a medication used to treat rheumatoid arthritis and other inflammatory disorders might also have therapeutic value for COVID-19 patients who have developed or at high risk of developing serious lung damage from SARS-CoV-2 infections.

29 Apr 2020

Researchers test existing anti-inflammatory drug in COVID-19 patients

An anti-inflammatory drug developed at Scripps Research 25 years ago is now being tested as a way to prevent acute respiratory distress in patients with COVID-19, the pandemic disease caused by the novel coronavirus.

29 Apr 2020

Study marks a major step towards beta cell replacement therapy

The loss of insulin-secreting beta cells by autoimmune destruction leads to type 1 diabetes. Clinical islet cell transplantation has the potential to cure diabetes, but donor pancreases are rare.

28 Apr 2020

Study: JNK and BNP activity can reverse cardiovascular damage, reduce risk of death from sepsis

Overreaction is rarely useful, and in the case of the human immune system, it can be outright deadly. When the body overreacts to an infection, the result is sepsis - a life-threatening condition that frequently leads to acute organ dysfunction, including deterioration of the heart and blood vessels, which make up the cardiovascular system.

24 Apr 2020

Research looks at best ways to tackle coronavirus crisis

A new study published in the journal Frontiers in Microbiology in April 2020 discusses the most attractive approaches among the broad spectrum of experimental and theoretical strategies being worked on to counter the COVID-19 pandemic.

24 Apr 2020

Sphere Fluidics receives Queen’s Award for Enterprise

Sphere Fluidics, has be honored with a Queen’s Award for Enterprise for Innovation.

From Fluidic Sciences and Sphere Bio 21 Apr 2020

Discovery could open door to the development of new anti-cancer drugs

A team of scientists led by the University of Michigan Rogel Cancer Center and Case Comprehensive Cancer Center has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.

20 Apr 2020

Researchers discover unique structure and function of rotavirus VP3 protein

After eluding researchers for more than 30 years, the VP3 protein of rotavirus has finally revealed its unique structure and function to a team led by scientists at Baylor College of Medicine.

17 Apr 2020

Gimsilumab trial starts in first US patient with ARDS and COVID-19

The first American patient with COVID-19 and acute respiratory distress syndrome (ARDS) has been put on the drug gimsilumab at Temple University Hospital, as part of the BREATHE clinical trial. The trial, sponsored by Roivant Sciences, will evaluate the effectiveness of intravenous gimsilumab in preventing death in patients with COVID-19 and ARDS.

16 Apr 2020

Alzheimer's disease: high amyloid levels linked to early disease

A new study published in the journal JAMA Neurology in April 2020 seems to indicate that higher brain amyloid levels represent early Alzheimer's disease (AD).

6 Apr 2020

Evinacumab drug reduces cholesterol levels in patients with rare cholesterol disorder

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol to near-normal levels among patients with a rare cholesterol disorder, meeting the primary endpoint in the first randomized placebo-controlled trial of the drug, which is being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

31 Mar 2020

Monoclonal antibody reduces LDL cholesterol in adult patients with HoFH

The cholesterol drug alirocumab reduced low-density lipoprotein (LDL) cholesterol by 35.6% compared to placebo in adult patients with homozygous familial hypercholesterolemia (HoFH), according to a phase three clinical trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

UC Davis launches two clinical trials to evaluate treatments for COVID-19

UC Davis Health has two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.

27 Mar 2020